157 related articles for article (PubMed ID: 18544420)
1. Monitoring inhibitor patients with the right assays.
Barrowcliffe TW
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S25-30. PubMed ID: 18544420
[TBL] [Abstract][Full Text] [Related]
2. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
[TBL] [Abstract][Full Text] [Related]
4. Views on methods for monitoring recombinant factor VIIa in inhibitor patients.
Key NS; Nelsestuen GL
Semin Hematol; 2004 Jan; 41(1 Suppl 1):51-4. PubMed ID: 14872422
[TBL] [Abstract][Full Text] [Related]
5. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.
Dargaud Y; Lienhart A; Meunier S; Hequet O; Chavanne H; Chamouard V; Marin S; Negrier C
Haemophilia; 2005 Sep; 11(5):552-8. PubMed ID: 16128902
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents.
Ananyeva NM; Lee TK; Jain N; Shima M; Saenko EL
Semin Thromb Hemost; 2009 Nov; 35(8):735-51. PubMed ID: 20169510
[TBL] [Abstract][Full Text] [Related]
7. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
8. Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors.
Kenet G; Martinowitz U
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S38-41. PubMed ID: 18544424
[TBL] [Abstract][Full Text] [Related]
9. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
[TBL] [Abstract][Full Text] [Related]
10. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry.
Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M
J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Monahan PE; Aledort LM;
Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
[TBL] [Abstract][Full Text] [Related]
12. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents.
van Veen JJ; Gatt A; Bowyer AE; Cooper PC; Kitchen S; Makris M
Int J Lab Hematol; 2009 Apr; 31(2):189-98. PubMed ID: 18190585
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
15. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts HR
Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
[No Abstract] [Full Text] [Related]
16. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
[TBL] [Abstract][Full Text] [Related]
17. High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors.
Kenet G
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S108-10. PubMed ID: 16427376
[TBL] [Abstract][Full Text] [Related]
18. [Acquired hemophilia: current status in Japan and immuno-biochemical features of autoantibodies to factor VIII].
Tanaka I; Shima N
Rinsho Ketsueki; 2005 Feb; 46(2):91-8. PubMed ID: 16447701
[No Abstract] [Full Text] [Related]
19. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
20. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor.
Faranoush M; Abolghasemi H; Mahboudi F; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M
Clin Appl Thromb Hemost; 2016 Mar; 22(2):184-90. PubMed ID: 25343955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
